Panelists discuss how recent trials, including KEYNOTE-057, QUILT-3.032, and CORE-001, highlight the promising efficacy, durability, and manageable safety profiles of novel treatments like pembrolizumab, nogapendekin alfa inbakicept, and nadofaragene firadenovec, while also exploring the potential of combination therapies and novel intravesical options like TAR-200 and UGN-102 for improving outcomes in non–muscle-invasive bladder cancer (NMIBC).
Panelists discuss how the ongoing ABLE-32 and ABLE-41 trials are exploring the efficacy and safety of nadofaragene firadenovec in different NMIBC patient populations, with ABLE-32 focusing on intermediate-risk patients and ABLE-41 examining real-world effectiveness and safety.
Paul E. Dato, MD, discusses how treatment selection between triplet therapy, doublet therapy, or androgen deprivation monotherapy should be based on disease volume, risk factors, patient age, fitness for chemotherapy, and patient preferences through shared decision-making.
“Widespread adoption of the BCG plus mitomycin regimen would actually help to resolve that BCG shortage," says Professor Dickon Hayne.
The investigators assessed EFS data from the CREST trial based on subgroups stratified by disease stage.
Explore the potential of ultra-low PSA testing in managing metastatic hormone-sensitive prostate cancer, balancing accessibility and cost considerations.
Explore the latest advancements in clinical trials for metastatic hormone-sensitive prostate cancer, focusing on innovative treatments and testing methods.
Emerging data on mHSPC shows promising trends in overall survival, highlighting the impact of care access and competing risks.
Panelists discuss how PET imaging for kidney cancer includes prostate-specific membrane antigen, which is sometimes expressed in renal cell carcinoma, though its utility remains unclear, whereas fluorodeoxyglucose PET can be useful for metabolic activity assessment despite limitations with inflammatory lesions.
Panelists discuss how to manage the treatment of a 68-year-old woman with painless intermittent hematuria and positive cytology for high-grade urothelial cancer, addressing gender differences in diagnosis timing, the importance of repeat transurethral resection (TURBT) procedures, BCG therapy options, and considerations for radical cystectomy with pelvic organ preservation when BCG fails.
Panelists discuss how deep learning applied to imaging data sets may advance kidney cancer assessment, though they believe the next major leap will require true molecular imaging that reveals what tumors are expressing.
This study highlights the safety of mHSPC drugs in black men, supported by both trial data and real-world evidence.
At a median follow-up of 61.4 months, enzalutamide plus ADT continued to show an improvement in OS vs ADT alone.
Hayne finds the emergence of antibody drugs conjugates in urothelial cancer to be particularly intriguing.
Campbell emphasized that although gender representation in medicine is shifting, structural and cultural biases continue to influence academic recognition.
Panelists discuss how the ongoing BCG shortage has forced clinicians to adapt treatment strategies for non–muscle-invasive bladder cancer (NMIBC), balancing resource constraints with patient outcomes through dose adjustments, chemotherapy substitution, and earlier cystectomy, while emphasizing the importance of maintaining trial eligibility and adhering as closely as possible to evidence-based protocols.
Panelists discuss evolving strategies for managing non–muscle-invasive bladder cancer (NMIBC), highlighting how risk stratification, resource limitations, and emerging therapies like gemcitabine-docetaxel are shaping treatment decisions, while emphasizing the urgent need for predictive tools and biomarkers to guide personalized care.
The study compared patient experiences with silicone vs polyurethane ureteral stents.
“It is possible to conserve fluid when we're trying to do these procedures without compromising patient care," says Roshan M. Patel, MD.
Paul E. Dato, MD, discusses how the absence of genetic alterations in the second case makes the patient ineligible for PARP inhibitor therapy until castration resistance develops, with focus remaining on ADT, AR-targeted therapy, chemotherapy, and bone support.
Panelists discuss how real-world data from a recent Mayo Clinic study confirms the promising efficacy and favorable safety profile of nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting high cystectomy-free and overall survival rates, with longer follow-up needed to assess response durability.
Panelists discuss how nogapendekin alfa, an intravesical immunotherapy that stimulates a localized immune response, combined with BCG therapy, provides a novel dual approach for treating BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), targeting both local and systemic immune responses.
Paul E. Dato, MD, discusses how triplet therapy involving ADT, docetaxel chemotherapy, and an androgen receptor targeting agent would be the best treatment option for this patient with high-volume, high-risk symptomatic metastatic disease including hepatic involvement.
The test demonstrated comparable or superior performance in Black and Non-White men.
"We...observed an exceedingly high degree of safety across the board, with very few complications,” says Jared S. Winoker, MD.
Jim C. Hu, MD, MPH, shares in-depth findings comparing urinary continence recovery across 3 RARP approaches.
“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” says Dean Elterman, MD.
Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.
Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.
